Compare · ATEC vs BDX
ATEC vs BDX
Side-by-side comparison of Alphatec Holdings Inc. (ATEC) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATEC and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 35.9x ATEC ($1.44B).
- Over the past year, ATEC is down 41.8% and BDX is down 2.2% - BDX leads by 39.6 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 5 for ATEC).
- BDX has more recent analyst coverage (25 ratings vs 20 for ATEC).
- Company
- Alphatec Holdings Inc.
- Becton Dickinson and Company
- Price
- -
- -
- Market cap
- $1.44B
- $51.69B
- 1M return
- +7.61%
- +19.45%
- 1Y return
- -41.83%
- -2.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 5
- 10
- Recent ratings
- 20
- 25
Alphatec Holdings Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest ATEC
- GENERAL COUNSEL & CORP. SEC. Marshall Tyson Eliot sold $78,821 worth of shares (8,168 units at $9.65) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 630,398 units (SEC Form 4) (for tax liability)
- SEC Form 10-Q filed by Alphatec Holdings Inc.
- SEC Form S-8 filed by Alphatec Holdings Inc.
- Alphatec Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ATEC Reports Second Quarter Financial Results
- UBS initiated coverage on Alphatec with a new price target
- ATEC Announces Participation in Upcoming Investor Conferences
- Stephens initiated coverage on Alphatec with a new price target
- ATEC to Report Second Quarter 2026 Financial Results on August 4, 2026
- BMO Capital Markets initiated coverage on Alphatec with a new price target
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results